Detalhe da pesquisa
1.
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Breast Cancer Res
; 25(1): 112, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37784176
2.
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.
Oncologist
; 28(2): 172-179, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493359
3.
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Cancer
; 128(17): 3224-3232, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767226
4.
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
Oncologist
; 27(10): 811-821, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917168
5.
p27 transcriptionally coregulates cJun to drive programs of tumor progression.
Proc Natl Acad Sci U S A
; 116(14): 7005-7014, 2019 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30877256
6.
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Breast Cancer Res
; 23(1): 85, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34392831
7.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Lancet
; 395(10226): 817-827, 2020 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145796
8.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
J Natl Compr Canc Netw
; : 1-8, 2021 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761455
9.
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Cancer
; 125(4): 541-549, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30422308
10.
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
Curr Oncol Rep
; 21(3): 25, 2019 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30806829
11.
The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer.
Ann Oncol
; 34(12): 1071-1073, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072508
12.
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Haematologica
; 102(4): 719-727, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28034990
13.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Oncologist
; 21(2): 214-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26834160
14.
Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Breast Cancer Res Treat
; 156(2): 405-6, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993130
15.
Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.
Lancet Oncol
; 20(6): 746-748, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036469
16.
Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
Clin Cancer Res
; 30(10): 2008-2010, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319645
17.
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Expert Rev Anticancer Ther
; 24(6): 397-405, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38642015
18.
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
JCO Oncol Pract
; 20(1): 69-76, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37922440
19.
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
Clin Cancer Res
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709212
20.
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Breast Cancer Res Treat
; 138(2): 369-81, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23430223